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Original Article
Adipose-derived stem cells protect
motor neurons and reduce glial activation
in both in vitro and in vivo models of ALS
Yuri Ciervo,1 Noemi Gatto,1 Chloe Allen,1 Andrew Grierson,1 Laura Ferraiuolo,1 Richard J. Mead,1,2
and Pamela J. Shaw1,2
1Sheffield Institute for Translational Neuroscience (SITraN), Department of Neuroscience, Faculty of Medicine, Dentistry and Health, The University of Sheffield, 385
Glossop Rd., Sheffield S10 2HQ, UK
Amyotrophic lateral sclerosis (ALS) is a devastating neurode-
generative condition for which new therapeutic options are ur-
gently needed. We injected GFP+ adipose-derived stem cells
(EGFP-ADSCs) directly into the cerebrospinal fluid (CSF) of
transgenic SOD1G93A mice, a well-characterized model of fa-
milial ALS. Despite short-term survival of the injected cells
and limited engraftment efficiency, EGFP-ADSCs improved
motor function and delayed disease onset by promoting motor
neuron (MN) survival and reducing glial activation. We then
tested the in vitro neuroprotective potential of mouse ADSCs
in astrocyte/MN co-cultures where ALS astrocytes show neuro-
toxicity. ADSCs were able to rescue MN death caused by ALS
astrocytes derived from symptomatic SOD1G93Amice. Further,
ADSCs were found to reduce the inflammatory signature of
ALS astrocytes by inhibiting the release of pro-inflammatory
mediators and inducing the secretion of neuroprotective
factors. Finally, mouse ADSCs were able to protect MNs
from the neurotoxicity mediated by human induced astrocytes
(iAstrocytes) derived from patients with either sporadic or
familial ALS, thus for the first time showing the potential ther-
apeutic translation of ADSCs across the spectrum of human
ALS. These data in two translational models of ALS show
that, through paracrine mechanisms, ADSCs support MN sur-
vival and modulate the toxic microenvironment that contrib-
utes to neurodegeneration in ALS.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenera-
tive condition characterized by the selective loss of both upper and
lower motor neurons (MNs) leading to muscle denervation, paralysis,
and ultimately death within 2–5 years from diagnosis.1 ALS is mainly
sporadic (sALS) in origin, but familial forms of the disease (fALS) ac-
count for 10% of cases.2 Mutations in the superoxide dismutase 1
(SOD1) gene are responsible for 15%–20% of fALS.3 Transgenic
mice expressing a high copy number of the human SOD1 gene
harboring the G93A mutation (SOD1G93A) recapitulate several clin-
ical and pathological features seen in the human disease and represent
a validated and robust model to investigate new therapeutic strate-
gies.4,5 ALS is a multifactorial disease where several impaired molec-
ular mechanisms are involved, including mitochondrial dysfunction,
protein mis-localization and aggregation, glutamate excitotoxicity,
impaired axonal transport, oxidative stress, and dysregulation of
RNA processing.6–9 Moreover, damage to MNs and disease progres-
sion are strongly amplified by dysfunction and aberrant activation of
non-neuronal cells such as astrocytes and microglia.10–12 Because of
the complexity and non-cell-autonomous nature of the disease, ther-
apeutic approaches targeting multiple mechanisms have been pro-
posed to be beneficial in ALS.13,14
The use of stem cells as a therapeutic tool for ALS is a therapeutic
approach with potential for targeting multiple disease mechanisms.15
Mesenchymal stem cells (MSCs) can be obtained from adults, show
low immunogenicity, and can target multiple disease pathways
through immunomodulation and secretion of trophic factors, cyto-
kines, and exosomes.14 In several studies, MSCs transplanted intrave-
nously, intraparenchymally, intrathecally, or intramuscularly were
able to ameliorate the phenotype of SOD1G93A rodents by improving
motor function, reducing neuroinflammation, slowing disease pro-
gression, and extending lifespan.14 Since the therapeutic effects of
MSCs seem to be mediated through paracrine effects rather than
cell replacement, direct delivery of cells into the cerebrospinal fluid
(CSF) may provide the safest and most efficacious delivery route in
order to modulate the toxic environment leading to motor neuron
degeneration.16–20 For several years, bone marrow aspirates have
been considered the reference source for MSCs (BM-MSCs).
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However, bone marrow aspiration is expensive and invasive and gives
rise to a limited number of stem cells.21 Adipose tissue may represent
a valid alternative source of MSCs for clinical application.22,23 Indeed,
adipose-derived stem cells (ADSCs) can be harvested through a less
invasive procedure such as liposuction, are more abundant, and
show greater ex vivo proliferative capacity and a lower senescence ra-
tio compared with BM-MSCs.24–27
In the present study, we investigated the therapeutic potential of
mouse-derived ADSCs in both in vivo and in vitro models of ALS.
First, we tested the efficacy of intrathecal transplantation of ADSCs
in pre-symptomatic SOD1G93A mice of the defined C57BL/6J genetic
background by evaluating motor performance, disease onset, and
CNS pathology. We also monitored the survival, engraftment, and
distribution of ADSCs over time by histological analysis. In the sec-
ond part of the study, we tested the neuroprotective potential of
ADSCs in astrocyte/MN co-cultures where ALS astrocytes (derived
from either SOD1G93A mice or human ALS patients) show neurotox-
icity.28–30 We then explored the immunomodulatory potential of
ADSCs in vitro by evaluating the secretion of pro-inflammatory me-
diators and growth factors from SOD1G93A mouse astrocytes, utiliz-
ing separated co-cultures. Our data in two translational models of
ALS indicate that the therapeutic potential of ADSCs is mediated
by the release of soluble factors able to directly and indirectly support
MN survival and reduce neuroinflammation.
RESULTS
Characterization of mouse adipose-derived stem cells
Mouse ADSCs (mADSCs) were isolated from the inguinal fat pads of
healthy 8- to 10-week-old non-transgenic (NTg) C57BL/6 mice,
expanded in vitro for 5 passages, and phenotypically and functionally
characterized as previously described.31 The immunophenotype of
ADSCs was determined by flow cytometry. ADSCs expressed the
mesenchymal stem cell surface markers (CD44, CD90, CD29,
CD106, and CD105) but were negative for CD73 and endothelial
(CD31) and hematopoietic (CD34, CD11b, CD45) markers (Fig-
ure 1A). A tri-lineage differentiation assay confirmed the multipoten-
tial differentiation capability of ADSCs (Figure 1B).
Transplanted EGFP-ADSCs engraft and survive in the
subarachnoid space of SOD1G93A mice
To monitor in vivo biodistribution, ADSCs were infected with lenti-
virus encoding enhanced green fluorescent protein (EGFP). Fluores-
cent microscopy and flow cytometry showed high transduction effi-
ciency (>98%) and robust expression of EGFP (Figures S1A and
S1B). To exclude alteration of cell characteristics following integra-
tion of EGFP into the genome, EGFP-ADSCs were subjected to
phenotypic and functional analysis as before, indicating no change
in either surface marker expression or differentiation capacity (Fig-
ures S2A and S2B).
In order to achieve both brain and spinal cord distribution of ADSCs
in transplantedmice, 5 105 EGFP-ADSCs were injected directly into
the CSF of 30-day-old SOD1G93A mice via the cisterna magna. Cell
dosage was chosen based on the literature18,32 and on pilot studies
(data not shown). To evaluate engraftment and survival of the injected
EGFP-ADSCs, mice were sacrificed 7-, 14-, 21-, and 28-days post-
transplantation (n = 3 per group). In order to preserve the meninges
and allow detection of cells within the subarachnoid space, the brain
and spinal cord were processed and carefully dissected with intact
dura mater as previously described.32 At 1 week post-injection, most
of the detected cells were found in clusters close to the site of injection
(cisterna magna) and in the IV ventricle (Figure 2A). Clusters of GFP+
cells were also found around the brainstem (cisterna pontine) (Fig-
ure 2B) and lateral recesses (Figure 2C) and along the spinal cord
(at cervical, thoracic, and lumbar levels) confined to the subarachnoid
space (Figure 2D). Two weeks after injection, EGFP-ADSCs were still
detected in the IV ventricle (Figure 2E), cisterna pontine (Figure 2F),
and lateral recesses close to the choroid plexus (Figure 2G), where oc-
casionally cells were found tomigrate into the brainstem. Interestingly,
ADSCs that survived in the subarachnoid space of the spinal cord
migrated toward both dorsal and ventral root ganglia (Figure 2H);
however, no cells have penetrated. Three weeks post-transplantation,
the survival of EGFP-ADSCs within the IV ventricle and cisterna
pontine decreased considerably (Figures 2I and 2J), while clusters of
GFP+ cells persisted in the lateral recesses (Figure 2K). Cells were still
detected in the subarachnoid space of the spinal cord (Figure 2L). At
week 4, very few EGFP-ADSCs were found to survive within the ven-
tricular system andwere confined to the spinal cordmeninges (Figures
2M–2P). No fluorescent signal was detected in control phosphate-
buffered saline (PBS)-injected mice (Figures 2Q–2T).
Intrathecal injection of EGFP-ADSCs improves motor function
and delays disease onset in SOD1G93A mice
We next investigated whether intrathecal transplantation of EGFP-
ADSCs into pre-symptomatic transgenic SOD1G93A mice could delay
motor functiondecline and theonset of visible signs of disease as a proof
of concept for therapeutic intervention. In our congenic strain of trans-
genic SOD1G93Amice, a significant decline in motor function is detect-
able by rotarod as early as 40 days of age before visible signs of the
disease are detected.33This allows the design of a relatively short proto-
col for preclinical therapeutic investigation (Figure 3A). Mice between
30 and 32days of agewere randomly assigned to theEGFP-ADSC treat-
ment (5 105EGFP-ADSCs, n = 15) or vehicle (PBS, n = 15) group. To
evenly distribute the parentage, litterswerematched between treatment
groups. ADSC-injected mice showed a significant increase in body
weight comparedwith the vehicle group from60days of age, which per-
sisted until the end of the study (PBS-injected mice 16.0 g (±0.8 SD) at
90 days versus EGFP-ADSC-injected mice 17.5 g (±0.9 SD), overall
treatment effect of p < 0.0001, 2-way ANOVA; p = 0.0012 at 90 days,
Bonferroni post-test; Figure 3B). Stem cell-transplanted mice per-
formed better on the rotarod task throughout the study compared
with PBS-injected mice (overall treatment effect of p = 0.039, 2-way
ANOVA; Figure 3C). Motor performance decline, measured as 20%
reduction from peak of performance,33 was significantly delayed in
ADSC-transplanted mice by 2 weeks (PBS-injected mice 7.4 weeks
(±2.0 SD) versus EGFP-ADSC injected mice 9.3 weeks (±2.3 SD), p =
0.026, Mann-Whitney test; Figure 3D). Onset of visible signs of disease
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defined by hindlimb splay defect plus tremor was also delayed by 5 days
in ADSC-injected mice compared with controls (PBS-injected mice
68.1 days (±4 SD) versus EGFP-ADSC-injected mice 73.5 days (±3.5
SD), p = 0.0005, unpaired t test; Figure 3E). We performed CatWalk
gait analysis at time points previously identified as informative ofmotor
impairment33 (days 70 and 84, n = 5/group). ADSC-treated mice
showed significant improvements in gait parameters compared with
the vehicle group (Figure S3).
Intrathecal injection of ADSCs protects motor neurons and
reduces glial activation in SOD1G93A mice
To investigate whether the therapeutic effects noted above result from
protection of MNs, we performed Nissl staining on lumbar spinal
cord sections obtained from 90-day-old mice (n = 6 per group) and
counted large MNs within the ventral horn. ADSC-injected mice
had significantly more MNs compared with the PBS-injected control
group (PBS-injected mice 2.5 MNs (±0.2 SD) per ventral horn
(10-mm-thickness sections) versus EGFP-ADSC injected mice 3.1
MNs (±0.4 SD) per ventral horn, p = 0.0434, 1-way ANOVA with
Tukey’s test; Figures 4A and 4B).
There is evidence that MN death in ALS could result from aberrant
glial activation, which in itself is a hallmark of disease progression
in ALS.12 To determine whether this may be a relevant mechanism
in the ADSC therapeutic effect, we performed immunohistochemistry
on the lumbar enlargement of the spinal cord of 90-day-old mice to
Figure 1. Isolated mADSCs display the expected surface markers and tri-lineage differentiation capacity
ADSCs were isolated from mouse inguinal fat pads and expanded in vitro. Immunophenotyping and differentiation capacity were evaluated to confirm their identity. (A)
Immunophenotype of mADSCs at passage 5 by flow cytometry analysis. The histogram in blue represents the cells stained with the specific antibody, and in red is rep-
resented the staining with the isotype-matched control antibody. On the abscissa is indicated the fluorescence intensity and on the ordinate the cell counts. The percentage
of positive cells is relative to the intensity of the isotype controls. mADSCs were negative (<0.5%) for the hematopoietic and endothelial markers CD34, CD31, CD11b, and
CD45, while CD73 was expressed in <3% of the total cell population. Notably, mADSCs were positive (>90%) for the MSC markers CD44, CD90, CD29, and CD106. The
expression of CD105 was detected in 54% of mADSCs. Percentage values represent average from 3 independent experiments ± SD. (B) Tri-lineage differentiation of
mADSCs after exposure to specific inductionmedia (seeMaterials andmethods). From left to right, adipogenesis was confirmed by oil red O staining, osteogenesis by alizarin
red O staining, and chondrogenesis by Alcian blue staining. Images are representative of at least 3 independent experiments.
www.moleculartherapy.org
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evaluate astrogliosis (glial fibrillary acidic protein [GFAP] staining)
and microgliosis (Iba-1 staining). Astrocyte activation, evaluated by
GFAP total staining area, was significantly reduced in ADSC-treated
mice compared with vehicle-treated mice (PBS-injected mice
7,191 mm2 (±634 SD) versus EGFP-ADSC-injected mice 6,203 mm2
(±774 SD) (10-mm-thickness sections), n = 6/group, p = 0.0413,
1-way ANOVA with Tukey’s test; Figures 4A and 4B; Figures S4A
and S4B). Microglial activation, defined by IBA-1 total staining
area, was also significantly attenuated in ADSC-recipient mice
compared with control mice (PBS-injected mice 2,921 mm2 (±154
SD) versus EGFP-ADSC-injected mice 2,075 mm2 (± 67 SD) (10-
mm-thickness sections), n = 6/group, p < 0.0001, 1-way ANOVA
with Tukey’s test; Figures 4C and 4D; Figures S4A and S4B). These
results are in agreement with a beneficial clinical effect on MN sur-
vival associated with a reduction in the spinal cord inflammatory
milieu mediated by astrocyte and microglial activation.
ADSCs protect motor neurons from SOD1G93A astrocyte toxicity
in vitro
Astrocytes are recognized to be key players in triggeringMNdeath and
disease progression in ALS.12 Previous studies showed that astrocytes
derived from SOD1G93Amice are toxic to wild-typeMNs in co-culture
systems.28,34 To directly test whether our in vivo observations in the
SOD1G93A mice were linked to ADSC-mediated protection against
toxic astrocytes, we took advantage of a separated triple-co-culture
method in which ADSCs are physically separated from MN/astrocyte
mixed co-cultures but able to communicate through the exchange of
soluble factors (Figure 5A). Briefly, healthy wild-type murine
Hb9-EGFP-MNs were co-cultured with mouse cortical astrocytes
(mAstrocytes) derived from either NTg or SOD1G93A genetically
matched mice. mADSCs were seeded onto modified glass coverslips
so to be added on top of the astrocyte/MN mixed co-culture without
being physically in contact.28mAstrocytes were isolated and expanded
from symptomatic (90 day old) SOD1G93Amice and age-matched con-
trol NTg mice. By flow cytometry analysis, the astrocyte cultures were
strongly positive for the astrocytic marker CD44 (>98% of cells) and
largely depleted (<0.5% of cells) of cells positive for the microglial
marker CD11b (Figure S5). Hb9-EGFP-MNs were obtained from
mouse embryonic stem cells (mESCs) containing an EGFP gene under
the MN-specific Hb9 promoter35 and added to the astrocytes at day 7
of differentiation. At day 1 and day 7 of co-culture, Hb9-EGFP-MNs
were imaged and counted. After 7 days in culture, there was a modest
but significant reduction (15%, p = 0.008, 2-wayANOVAwith Tukey’s
test; Figures 5B and 5C) in survival of Hb9-EGFP-MNs in the
SOD1G93A astrocyte cultures compared with control NTg cultures,
confirming that SOD1G93A astrocytes are toxic and/or less able to sup-
port MN survival in vitro.28,36 The presence of ADSCs in the
SOD1G93A co-culture resulted in a significant increase of 23% in
MN viability compared with untreated SOD1G93A cultures, abolishing
the toxicity observed under basal conditions (p = 0.0002, 2-way
ANOVAwith Tukey’s test; Figures 5B and 5C). Furthermore, MN sur-
vival in SOD1G93A cultures containing ADSCs was 7% higher than
untreated NTg culture (p = 0.043, 2-way ANOVA with Tukey’s test;
Figures 5B and 5C). Interestingly, ADSCs also affected NTg astro-
cyte/MN co-cultures, improving MN survival by 15% (p = 0.0021,
2-way ANOVA with Tukey’s test; Figures 5B and 5C). Given that in
the presence of ADSCs an increase in MN survival was also observed
in the control NTg astrocyte cultures, further co-culture experiments
were carried out in order to determine whether the mechanism of pro-
tection was due to direct MN support rather than the ability of ADSCs
to reduce the ALS astrocyte toxicity. Hb9-EGFP-MNs were seeded on
laminin-coated plates and cultured for 3 days alone or in the presence
of ADSCs (separated co-culture). The relative percentage of MN sur-
vival from day 1 to day 3 was then calculated and compared. Although
non-statistically significant, an increase of 17% in MN survival
was observed when the motor neurons were co-cultured with ADSCs
(p = 0.3613, paired t test; Figure S6).
ADSCs secrete VEGF and IGF-1 and modulate the secretion of
these neurotrophic factors by mouse astrocytes
One of the proposed mechanisms of neuroprotection by ADSCs is
their ability to secrete high levels of growth factors including vascular
endothelial growth factor (VEGF) and insulin-like growth factor-1
(IGF-1).23,37Moreover, there is evidence that these cells have the abil-
ity to respond differently according to the external stimuli to which
they are exposed.38,39 Here, by using a separated co-culture method
(Figure 6A), we evaluated the secretion of VEGF and IGF-1 by ELISA
in supernatants of control unstimulated ADSCs and ADSCs co-
cultured with either NTg or SOD1G93A astrocytes. Separated co-cul-
tures of ADSCs and astrocytes were maintained for 48 h. At the
end of the 48-h co-culture ADSCs and astrocytes were separated
and cultured alone for 24 h. The supernatant from both astrocytes
and ADSCs was collected and growth factor release measured. In
monocultures, ADSCs were able to secrete detectable levels of both
Figure 2. Survival and distribution of transplanted EGFP-ADSCs in SOD1G93A mice
(A–D) Week 1 post-injection. (E–H) Week 2 post-injection. (I–L) Week 3 post-injection. (M–P) Week 4 post-injection. (Q–T) PBS injection. At 1 week from post-injection,
clusters of EGFP-ADSCs were mostly found within the ventricular system close to the site of injection and in the IV ventricle (A), at the base of the brainstem (B), in the lateral
recesses (C), and within the subarachnoid space of the spinal cord at cervical, thoracic, and lumbar levels (D). After 2 weeks, the majority of GFP+ cells were found in the IV
ventricle (E) and in the lateral recesses close to the choroid plexus (G). Cells were also detected in the cisterna pontine and around the brainstem, where a few cells migrated
into the parenchyma (F). EGFP-ADSCs in the subarachnoid space of the spinal cord migrated close to both dorsal and ventral roots; however, no cells were found to
penetrate through themeninges (H). After 3weeks, cells were still present in the IV ventricle (I) and in the cisterna pontine (J); however, themajority of the cells were detected in
the lateral recesses (K). Cells were also detected in the subarachnoid space of the spinal cord close to ventral and dorsal roots especially at cervical and thoracic levels, with a
few cells surviving in the lumbar enlargement (L). After 4 weeks from injection, the survival of ADSCs markedly decreased. A few cells were detected in the ventricular system
and in the spinal cord meninges (M–P). No signal was detected in control PBS-injected mice (Q–T). Images were acquired with the IN Cell 2000 analyzer (GE Healthcare).
Nuclei were stained with DAPI. Scale bars: 200 mm all. IV Ve, fourth ventricle; Bs, brainstem; Cb, cerebellum; CM, cisterna magna; Cp, cisterna pontine; Lr, lateral recess;
ChP, choroid plexus; Cc, central canal; Dh, dorsal horn; Dr, dorsal root; Mg, meninges; ScLr, spinal cord lumbar region; Vr, ventral root.
www.moleculartherapy.org
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VEGF and IGF-1 (Figures 6B and 6C). Notably, compared with
monocultures, VEGF secretion in ADSCs was increased by 27% af-
ter co-culture with NTg astrocytes (p = 0.0135, 1-way ANOVA with
Tukey’s test; Figure 6B) and by46% after co-culture with SOD1G93A
astrocytes (p = 0.0002, 1-way ANOVA with Tukey’s test; Figure 6B).
Interestingly, co-culture with SOD1G93A astrocytes, but not with NTg
astrocytes, induced ADSCs to secrete significantly higher levels of
IGF-1 (p = 0.0003, 1-way ANOVA with Tukey’s test; Figure 6C).
ADSCs also seem to be able to modulate the expression levels of
growth factors in astrocytes.22,40 Thus, we evaluated the secretion of
VEGF and IGF-1 in both NTg and SOD1G93A astrocytes following
separated co-culture with ADSCs (Figure 6A). At basal levels,
SOD1G93A astrocytes secreted a significantly higher amount of
VEGF compared with NTg astrocytes (p = 0.0001, 1-way ANOVA
with Tukey’s test; Figure 6D). Interestingly, ADSC treatment
increased the secretion of VEGF in NTg astrocytes (p = 0.0178,
1-way ANOVA with Tukey’s test; Figure 6D), whereas it did not alter
VEGF secretion in SOD1G93A astrocytes. In contrast, secretion of
IGF-1 from untreated SOD1G93A astrocytes was significantly reduced
compared with untreated control NTg astrocytes (p < 0.0001, 1-way
ANOVA with Tukey’s test; Figure 6E). The presence of ADSCs in the
culture enhanced the secretion of IGF-1 in both NTg and SOD1G93A
astrocytes. In particular, IGF-1 secretion in SOD1G93A astrocytes was
increased by 5-fold (p = 0.0386, 1-way ANOVA with Tukey’s test;
Figure 6E).
ADSCs reduce secretion of inflammatory mediators by
SOD1G93A mouse astrocytes
Among several mechanisms by which ALS astrocytes exert neural
toxicity, increased secretion of inflammatory factors such as cytokines
and chemokines has been demonstrated previously.12,41,42Given their
immunomodulatory properties, we investigated whether, through
paracrine mechanisms, ADSCs could affect SOD1G93A astrocytes by
inhibiting the secretion of inflammatory mediators such as tumor ne-
crosis factor (TNF)-a, interleukin (IL)-6, Il-1b, and MCP-1. After the
separated co-culture experiment (Figure 7A), the secretion of pro-in-
flammatory cytokines was measured in the supernatant of NTg and
SOD1G93A astrocytes with the use of the Multiplex Cytometric Bead
Array (CBA) immunoassay. Under basal conditions (monocultures),
levels of TNF-a were slightly increased in the SOD1G93A astrocyte
supernatant compared with the NTg astrocyte culture; however, the
difference did not reach statistical significance (p = 0.2045, 1-way
ANOVA with Sidak’s test; Figure 7B). SOD1G93A astrocytes secreted
significantly higher levels of IL-6 (p < 0.0001, 1-way ANOVA with Si-
dak’s test; Figure 7C) and MCP-1 (p < 0.0001, 1-way ANOVA with
Sidak’s test; Figure 7E) compared with NTg control astrocytes,
whereas no difference was found in IL-1b secretion (Figure 7D).
Treatment with ADSCs inhibited the secretion of all four cytokines
tested in SOD1G93A astrocytes (Figures 7B–7E). In particular, after
co-culture with ADSCs secretion of TNF-a was reduced by 69%
(p = 0.0025, 1-way ANOVA with Sidak’s test; Figure 7B), IL-6 by
68% (p < 0.0001, 1-way ANOVA with Sidak’s test; Figure 7C), and
MCP-1 by 22% (p < 0.0001, 1-way ANOVA with Sidak’s test; Fig-
ure 7E), whereas IL-1b levels were not detectable in supernatant
from ADSC-treated astrocytes (Figure 7D).
ADSCs protect MNs from human ALS iAstrocyte toxicity in vitro
It has been shown that induced astrocytes (iAstrocytes) derived from
ALS patients (with familial or sporadic disease) are toxic to MNs in
culture.30,43 Here, we investigated whether the neuroprotective effect
of ADSCs on Hb9-EGFP-MNs in mouse SOD1G93A astrocyte co-cul-
tures could be translated to a human model of disease. Importantly,
this allowed us to test the therapeutic potential of ADSCs in both spo-
radic (sALS) and familial (fALS) cases of ALS (see Table S1 for patient
Figure 3. Intrathecal transplantation of ADSCs in SOD1G93A mice delays
motor function decline and onset of visible signs of disease
(A) Schematic diagram showing the “rapid” pre-clinical protocol in SOD1G93A mice.
Mice were injected with either 500,000 EGFP-ADSCs or PBS via the cisterna magna
at 30 days of age (4 weeks) (n = 15 per group). Body weight andmotor performance
were monitored twice per week. Gait analysis was performed at day 70 and day 84
with the use of the CatWalk on a subset of the main cohort (n = 5 per group). During
the study, EGFP-ADSC mice (n = 3 per group per time point) were sacrificed to
evaluate engraftment and survival of EGFP-ADSCs. The study terminated at day 90
(week 13). (B) ADSC-injected mice gained significantly more weight compared with
PBS-injected mice (p < 0.0001 for overall treatment effect, 2-way ANOVA; p values
for Bonferroni’s post tests at individual time points as indicated). (C) Treated mice
showed overall improved motor performance on the rotarod task (p = 0.039, 2-way
ANOVA). (D) Motor decline measured as the time taken to reach 20% reduction from
peak of performance on the rotarod was significantly delayed (median 7 weeks for
PBS injected, 9.5 weeks for ADSC injected, p = 0.0026, Mann-Whitney U test). (E)
Onset of visible signs of disease defined as the presence of tremor and a hindlimb
splay defect was significantly delayed in mice receiving ADSC treatment (68 ±
4 days for PBS, 73.5 ± 3.5 days for ADSC, p = 0.0005, unpaired t test). Error bars
denote SD; n = 15 per group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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details), an approach not possible for sALS because of the lack of
in vivo models. As expected, MN survival in ALS-derived iAstrocyte
cultures was reduced compared with control-derived iAstrocytes
(Figure 8). Remarkably, the presence of mADSCs protected MNs
from both sALS and fALS iAstrocytes regardless of the genetic
subtype. Interestingly, the protective effect was observed for some
but not all patients tested, with one sporadic and one SOD1-linked
iAstrocyte line being less responsive to the benefits of ADSC
exposure.
DISCUSSION
Previous studies demonstrated the efficacy of intrathecal transplanta-
tion of MSCs into SOD1G93A rodents (reviewed in Ciervo et al.14).
Moreover, phase I and II clinical trials have demonstrated that the in-
jection of MSCs directly into the CSF of ALS patients is safe and well
tolerated.44–46 However, further pre-clinical investigation to shed
light on the mechanisms of protection mediated via effects on neu-
rons and/or non-neuronal cells and the identification of the best
source of MSCs is still needed. Most of the previous studies trans-
planted MSCs derived from the bone marrow or umbilical cord.
However, adipose tissue may provide a better adult stem cell source
because of the ease and efficiency of obtaining clinically relevant
numbers of MSCs. In the current study, we evaluated the therapeutic
potential of mADSCs in ALS by using both in vivo and in vitromodels
of disease. Studies evaluating the therapeutic potential of MSCs in the
SOD1G93A murine model of ALS have been mostly carried out by
transplanting human cells.14 However, immunosuppression in recip-
ient rodents was often required in order to avoid rejection of the
Figure 4. ADSCs protect MNs and reduce neuroinflammation in SOD1G93A mice
PBS-injected mice (n = 6), ADSC-injected mice (n = 6), and wild-type non-transgenic (NTG) mice (n = 4) at day 90 were sacrificed and lumbar spinal cords processed for
histological examination. (A) Representative Nissl-stained lumbar spinal cord ventral horns. (B) The number of MNs was higher in ADSC-treated mice compared with the
vehicle (2.6 ± 0.2 MNs/ventral horn in PBS versus 3.1 ± 0.4 MNs/ventral horn in ADSC, p = 0.0434, 1-way ANOVAwith Tukey’s multiple comparison test). (C) Representative
images of GFAP staining in ventral horn of PBS-injected, ADSC-injected, and NTG mice. See also Figure S4A. (D) Quantification of GFAP staining measured as total staining
area. Astrocyte activation was reduced in ADSC-transplanted mice (7,191 ± 635 mm2 in PBS versus 6,203 ± 774 mm2 in ADSC, p = 0.413, 1-way ANOVA with Tukey’s
multiple comparison test). (E) Representative images of IBA-1 staining in PBS-injected, ADSC-injected, and NTG mice. See also Figure S4B. (F) IBA-1 total staining area
quantification showing reduced microgliosis in ADSC-transplanted mice compared with the vehicle (2,921 ± 154 mm2 for PBS versus 2,075 ± 67 mm2 for ADSC, p < 0.0001,
1-way ANOVA with Tukey’s multiple comparison test). Data are presented as mean ± SD. Scale bars: 50 mm all.
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transplanted human stem cells. The use of immunocompromised
ALS animals for the study of MSC transplantation is disadvantageous
for several reasons. Given that one of the protective mechanisms of
action of MSCs in ALS is based upon their immunomodulatory activ-
ity, the use of immunosuppressive agents could significantly alter
and/or mask important features of the transplanted cells and how
they respond to the ALS microenvironment. Moreover, an important
characteristic of MSCs is their low immunogenic profile, which would
facilitate both autologous and allogenic transplantation in humans. So
the introduction of an immunosuppressive regime when investigating
the therapeutic potential of MSCs in vivo could be controversial. For
these reasons, the in vivo work here presented focused on the use of
mADSCs, which avoided the need for immunosuppressive agents.
Our results indicate that a single intrathecal dose of ADSCs injected
into SOD1G93A mice at the pre-symptomatic stage is able to signifi-
cantly improve motor performance and delay disease onset through
MN protection and attenuation of glial activation. These data provide
evidence that ADSCs possess therapeutic properties similar to those
of BM-MSCs and umbilical cord MSCs (UC-MSCs) when injected
into the CSF of ALS mice. Importantly, in contrast to other studies
using transgenic SOD1G93A mice on the mixed B6SJLF1/J genetic
background, here mice of defined C57BL/6J genetic background
were used. The use of the mixed SLJB6 genetic background can
lead to a high degree of biological variability, which confounds inter-
pretation of the data.33,47 In contrast, our model shows minimal ge-
netic variation, reduced background noise in biological readouts,
and robust reproducibility of disease.33 A limitation of the present
work is that cells were transplanted before clinical signs of the disease
and mice were not followed until the end-stage. However, deficits in
motor performance in our model can be detected before clinical signs
of disease become evident.4 This initial deficit can be measured as a
20% reduction in rotarod performance, which correlates with early
denervation of motor endplates.33 This is an important feature of
the model, enabling investigation of therapeutic strategies during
early stages of disease, which may be crucial in the development of
therapies for human ALS.48 Of interest, in human patients decline
in physical performance and features of neurodegeneration are
observed before the diagnosis of ALS is established.49,50 Therefore,
here we demonstrated that ADSCs protected MNs during the first
stages of neuronal degeneration characterized by the initial loss of
neuromuscular junctions (NMJs).
We also qualitatively evaluated the distribution and engraftment of
EGFP-ADSCs throughout the CNS over time, showing that ADSCs
are able to survive in ALS mice for up to 1-month post-transplanta-
tion. Injection through the cisterna magna allowed the cells to widely
distribute within the brain ventricular system and to reach the level of
the lumbar spinal cord. In agreement with other studies,18,20,51
ADSCs did not migrate into the spinal cord parenchyma, thus rein-
forcing the notion that the beneficial effects observed are due to the
paracrine activity of ADSCs, with potential medium-term effects,
since increased numbers of surviving MNs and reduced glial activa-
tion were observed 2 months after stem cell application. Although
intrathecal delivery may represent the preferred route of administra-
tion of MSCs in ALS patients, methods to improve cell migration and
engraftment into the spinal cord parenchyma are needed. If on the
one hand clinical benefits could be achieved without integration
into the host spinal cord parenchyma, on the other hand multiple
and repeated injections might be necessary to achieve prolonged ben-
efits. This may represent an important limitation, because of the large
amount of cells needed and consequently the high costs related to
manufacturing, cell banking, and patient care/hospitalization. To bet-
ter understand whether intrathecal stem cell injection could effec-
tively produce beneficial effects in patients further studies are needed.
In our study ADSCs were injected at a pre-symptomatic stage, during
which inflammatory chemical signals such as chemokines and cyto-
kines necessary to activate or induce the homing properties of ADSCs
might not yet have been secreted at biologically relevant concentra-
tions.52 At a later stage of disease, a sustained inflammatory milieu
may allow MSCs to enter the parenchyma.17 Future studies injecting
cells after the onset of clinical signs of disease to evaluate engraftment,
disease progression, and survival are needed. In particular, it would
be highly informative to determine whether multiple repeated injec-
tions of ADSCs would be more effective compared with a single
administration.
Previous studies showed that conditioned medium from MSCs pro-
tected MNs against mechanical, oxidative, and apoptotic stress
in vitro.23,40,53 However, in these studies application of external stim-
uli such as treatment with H2O2, staurosporine, or manual scratch
were necessary in order to induce MN damage. In our study, through
paracrine mechanisms, ADSCs were able to protect MNs from
intrinsic SOD1G93A astrocyte toxicity. Thus, for the first time the neu-
roprotective potential of ADSCs in ALS models is demonstrated by
Figure 5. ADSCs protect MNs from SOD1G93A astrocyte toxicity and promote MN survival in NTg astrocyte cultures
(A) Schematic diagram showing astrocyte/Hb9-EGFP-MN/ADSC separated triple-co-culture system. MNs are seeded on a confluent layer of astrocytes and ADSCs onto
glass coverslips. Culture plates are imaged at days 1 and 7 with the IN Cell 2000 analyzer to identify live GFP-MNs. MN quantification is performed with the use of Columbus
software, which allows selection and counting of only GFP-positive cell bodies with at least two processes. (B) Representative images of Hb9-EGFP-MNs at days 1 and 7 of
co-culture with SOD1G93A or NTg astrocytes under basal conditions and in the presence of ADSCs (scale bars: 50 mm). (C) Quantification of motor neuron survival after 7 days
of co-culture. SOD1G93A astrocytes are toxic to MNs compared with NTg astrocyte co-cultures (71% ± 4%MN survival in NTg versus 61% ± 6% in G93A). ADSCs protected
MNs from G93A astrocyte toxicity (61% ± 6% in untreated versus 79% ± 4% in ADSC treated) and increased MN survival compared with untreated NTg astrocytes (7%).
ADSCs increased MN survival on NTg astrocyte co-cultures compared with untreated NTg astrocytes (71% ± 4% MN survival in untreated versus 83% ± 6% in ADSC
treated). MN quantification represents 3 independent experiments, where each experiment is in triplicate and consists of a different astrocyte preparation (2-way ANOVA,
plus Tukey’s multiple comparison test). *p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SD. G93A, SOD1G93A astrocytes; MN, motor neurons; NTg, non-transgenic
astrocytes.
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Figure 6. Modulation of VEGF and IGF-1 secretion in ADSC/mAstrocyte separated co-cultures
(A) Schematic diagram showing the astrocyte/ADSC separated co-culture system. Astrocytes are seeded on plastic culture wells and ADSCs onto glass coverslips. After 48 h
of separated co-culture, coverslips containing ADSCs are removed from the astrocytes and both ADSCs and astrocytes are maintained as monocultures for a further 24 h.
Supernatant from astrocytes and ADSCs is collected and the amount of growth factors measured by ELISA. (B) Without any stimulus, ADSCs secreted 2.94 ± 0.1 ng/mL of
VEGF. The presence of either NTg or SOD1G93A astrocytes induced ADSCs to secrete significantly more VEGF compared with ADSC monocultures. Co-culture with
SOD1G93A astrocytes induced significantly higher secretion of VEGF compared with ADSCs co-cultured with NTg astrocytes (3.99 ± 0.3 ng/mL in NTg versus
5.4 ± 0.4 ng/mL in SOD1G93A). (C) Secretion levels of IGF-1 were significantly increased in ADSCs co-cultured with SOD1G93A astrocytes compared with control
ADSC monocultures (62.39 ± 15.11 pg/mL in monocultures versus 350.2 ± 61.79 pg/mL in SOD1G93A) and compared with ADSCs cultured with NTg astrocytes
(114.5 ± 24.8 pg/mL in NTg versus 350.2 ± 61.79 pg/mL in SOD1G93A). (D) At basal levels SOD1G93A astrocytes secreted significantly more VEGF than control NTg
astrocytes (612 ± 62.5 pg/mL for NTg versus 1,531 ± 129.1 pg/mL for SOD1G93A). Co-culture with ADSCs induced a significant increase in VEGF secretion in NTg astrocytes
(legend continued on next page)
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adopting a less artificial in vitro system that more closely recapitulates
the environment in human ALS.
In agreement with recent evidence that astrocytes actively participate
in inflammation-mediated neuronal damage,12,41 SOD1G93A astro-
cytes secreted enhanced levels of pro-inflammatory cytokines
compared with NTg astrocytes. Notably, ADSCs modulated
astrocytic functions by reducing the secretion of pro-inflammatory
mediators such as Il-6, MCP-1, IL-1, and TNF and by enhancing
the production of the anti-inflammatory and neuroprotective factor
IGF-1. Thus, in addition to immunomodulation of peripheral im-
mune cells and resident microglia, MSCs showed the capacity to
reduce the pro-inflammatory signature in adult SOD1G93A astrocytes,
which actively contribute to neuroinflammation.40,54–56 ADSCs
secreted biologically relevant amounts of VEGF and IGF-1, which
were further increased after co-culture with SOD1G93A astrocytes,
confirming the capacity of MSCs to respond to the toxic ALS environ-
ment by producing factors that can directly and indirectly support
MNs.57–59 For instance, in independent studies IGF-1 has been shown
to not only protect MNs from excitotoxicity but also inhibit the in-
flammatory response in lipopolysaccharide (LPS)-stimulated astro-
cytes in vitro and to reduce astrogliosis in a rat model of brain
injury.60–62 VEGF has well-described neuroprotective actions and
has been shown to protect MNs against glutamate excitotoxicity,
as well as stimulating axonal growth and promoting synaptic
plasticity.57,63 Moreover, through the release of VEGF, IGF-1, and
hepatocyte growth factor (HGF), ADSCs improved the glutamate
recycling function in SOD1G93A astrocytes and protected neuronal
cells from apoptosis induced by oxidative stress.23,58,64
It is worth mentioning that a large body of research has explored the
therapeutic potential of directly delivering VEGF or IGF-1 into ALS
animal models.65 Interestingly, several strategies to enhance the con-
centration of these factors, alone or in combination, in brain, spinal
cord, or muscle of SOD1G93A mice improved motor performance,
slowed down disease progression, and extended lifespan through
MN protection, preservation of NMJ, and reduction of microgliosis.
Unfortunately, several clinical trials assessing the safety and efficacy
of direct injection of growth factors in ALS patients have fallen short
of expectations. Several hypotheses were raised to explain these fail-
ures, such as route of administration, dose, the inability of the factors
to cross the blood-brain barrier (BBB), and possibly the need to use a
combination of different growth factors that operate synergistically to
achieve therapeutic benefits.66 Although we do not have direct evi-
dence showing that IGF-1 and VEGF released by ADSCs are respon-
sible for the reduced MN death observed in our triple co-culture
system, the secretion of these factors from ADSCs is likely to have
contributed significantly to the therapeutic effects observed in our
studies. Further studies using neutralizing antibodies against VEGF
and IGF-1, or the use of RNA interference, may help to further eluci-
date the molecular mechanisms of protection.
Together with previous reports, we have presented evidence that the
therapeutic potential of ADSCs arises from a combination of mecha-
nisms that not only directly support MNs through, for example, the
uninterrupted secretion of growth factors and cytokines but also by
modulating astrocyte and microglial functions, culminating in the
generation of a neuroprotective environment.22,54,55 In addition to
growth factors and cytokines, ADSCs secrete exosomes, which pro-
tected MN-like NSC-34 SOD1G93A cells from an oxidative insult
and also alleviated protein aggregation and mitochondrial dysfunc-
tion in differentiated SOD1G93A neuronal stem cells.67,68
Although SOD1G93A mice represent a robust and well-characterized
model of ALS, SOD1mutations are responsible for a small percentage
of human ALS cases and several promising therapeutic approaches
tested in this model have failed to translate into human benefit.47
Here, as a proof of concept for translation into the human disease,
we showed that ADSCs have the capacity to protect MNs from
iAstrocyte toxicity, using cells derived from human patients with
either sporadic or familial disease caused by mutations in the
C9orf72 or SOD1 genes. Interestingly, each iAstrocyte cell line re-
sponded to the ADSC treatment to a different degree, with two cell
lines that did not show a significant positive response. This finding
highlights the importance of controlling for patient heterogeneity in
clinical trial enrollment and the need for patient stratification
methods when evaluating therapies in ALS. Further studies adopting
our in vitro system and investigations aimed to unravel the molecular
mechanisms of action of ADSCs on human iAstrocytes are of great
interest, potentially enabling the identification of responders and,
more importantly, of potential ADSC biological markers predictive
of a positive/negative therapeutic response.
MATERIALS AND METHODS
Isolation and expansion of mouse adipose-derived stem cells
mADSCs were isolated from 8- to 10-week-old female C57BL/6J mice
as previously described with minor modifications.69 Mice were sacri-
ficed by cervical dislocation, and inguinal (subcutaneous) fat pads
were aseptically removed and collected into a 50-mL Falcon tube con-
taining sterile ice-cold Hank’s balanced salt solution with Ca2+ and
Mg2+ (HBSS) (Gibco, Waltham, MA, USA) and 50 U/mL peni-
cillin-streptomycin (Pen/Strep) (Lonza, Basel, Switzerland). Before
proceeding to the mechanical disruption of the tissue, lymph nodes
were carefully removed to avoid leukocyte contamination. The tissue
(612 ± 62.5 pg/mL in untreated versus 1,001 ± 255.6 pg/mL in ADSC treated) but not in SOD1G93A astrocytes. (E) Secretion levels of IGF-1 were significantly reduced in
SOD1G93A astrocytes compared with control NTg astrocytes (131.6 ± 13.92 pg/mL for NTg versus 6.6 ± 3 pg/mL for SOD1G93A). The presence of ADSCs in the culture
induced the secretion of IGF-1 in both NTg (131.6 ± 13.92 pg/mL in untreated versus 162 ± 27 pg/mL in ADSC treated) and SOD1G93A (6.6 ± 3 pg/mL in untreated versus
38.6 ± 9 pg/mL in ADSC treated) astrocytes. Data are presented as mean ± SD; n = 3 separate experiments where each n consists of a different astrocyte preparation. Data
analyzed with 1-way ANOVA plus Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. G93A, SOD1G93A astrocytes; NTg, non-transgenic
astrocytes.
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was digested with 0.075% collagenase I (Sigma, St. Louis, MO, USA)
and 2% bovine serum albumin (BSA) (Sigma, St. Louis, MO, USA) at
37C in a water bath for 60–80 min with gentle shaking every 10 min.
The resulting homogenate was then filtered through a 70-mm sterile
mesh cell strainer (Fisher Scientific, Hampton, NH, USA) and centri-
fuged at 500  g for 5 min to obtain the stromal vascular fraction
(SVF). Contaminating red blood cells were lysed with red blood cell
lysis buffer (160 mM NaH4Cl, 14 mM NaHCO3, 0.1 mM EDTA;
Figure 7. Increased secretion of inflammatory cytokines in SOD1G93A astrocytes is downregulated after co-culture with ADSCs
(A) SOD1G93A and control NTg astrocytes were seeded and grown as monocultures before addition of ADSCs previously seeded onto glass coverslips. For controls, empty
coverslips were added to the astrocytes. Separated co-cultures were maintained for 48 h in basal astrocytic medium. Coverslips containing ADSCs were then removed and
astrocytes cultured for 24 h before supernatant collection and measurement of cytokines/chemokines with the use of the Multiplex Cytometric Bead Array (CBA) immu-
noassay. (B) SOD1G93A astrocytes secreted more TNF-a compared with controls (59.4 ± 19.6 pg/mL for NTg versus 81.7 ± 6.7 pg/mL for SOD1G93A) ,which decreased after
ADSC exposure (25.45 ± 2 pg/mL). (C) SOD1G93A astrocytes secreted more IL-6 than control astrocytes (96.8 ± 31.4 pg/mL for NTg versus 3,374 ± 339.2 pg/mL for
SOD1G93A), which was reduced after co-culture with ADSCs (1,104 ± 167 pg/mL). (D) No difference was found between SOD1G93A and control astrocytes in IL-1b secretion
(440 ± 340 fg/mL for NTg versus 301 ± 206 fg/mL for SOD1G93A). However, no detectable levels of IL-1b were found in the supernatant of ADSC-treated cultures. (E)
Secretion levels of the chemokine MCP-1 were upregulated in SOD1G93A astrocytes (811 ± 83 pg/mL for NTg versus 8,133 ± 543 pg/mL for SOD1G93A). ADSC exposure
reduced secretion of MCP-1 (6,346 ± 414 pg/mL). Data are presented as mean ± SD; n = 3 separate experiments where each n consists of a different astrocyte preparation.
Data analyzed with 1-way ANOVA plus Sidak’s multiple comparison test. **p < 0.01, ***p < 0.001, ****p < 0.0001. Error bars represent SD. G93A, SOD1G93A astrocytes; NTg,
non-transgenic astrocytes.
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pH 7.3) for 7 min at room temperature (RT) in the dark. Cells were
then filtered, washed in HBSS, and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Lonza, Basel, Switzerland) containing
4,500 mg/L glucose, L-glutamine, 10% fetal bovine serum (FBS)
(MSC-Qualified, 13662-011, Gibco, Waltham, MA, USA), and 1%
Pen/Strep. After 48 h, the non-attached cells and cellular debris
were removed by washing in PBS and fresh complete medium was
added. When cultures were 80% confluent, cells were detached with
trypsin-Versene-trypsin-EDTA (Lonza, Basel, Switzerland) and
plated for expansion at a seeding density of 5,000 cells/cm2. For ex-
periments, ADSCs were used at passages 3–5.
Flow cytometry
Cells were collected by trypsinization and counted, and viability was
determined by the trypan blue (Sigma, St. Louis, MO, USA) exclusion
method. Cells were not analyzed if viability was <90%. Cells were re-
suspended in ice-cold flow cytometry (FC) buffer, consisting of PBS
containing 2% FBS (Gibco, Waltham, MA, USA) and aliquoted into
microcentrifuge tubes at a concentration of 5  105 cells/tube. After
10-min incubation on ice, cells were washed by centrifugation and
incubated on ice for 30 min with the specific fluorescent labeled
monoclonal antibody. The following antibodies were used: mouse
anti-CD90-phycoerythrin (PE) (0.15 mg/5  105 cells), mouse anti-
CD44-allophycocyanin (APC) (0.13 mg/5  105 cells), mouse anti-
CD106-phycoerythrin-cyanine7 (PE-Cy7) (0.20 mg/5  105 cells),
mouse anti-CD45-fluorescein isothiocyanate (FITC) (0.15 mg/5 
105 cells), mouse anti-CD34-PE (0.13 mg/5  105 cells), mouse
anti-CD31-APC (0.15 mg/5  105 cells), mouse anti-CD29-PE-Cy7
(0.50 mg/5  105 cells), mouse anti-CD105-PE-Cy7 (0.50 mg/5 
105 cells), and mouse anti-CD11b-FITC (0.13 mg/5  105 cells). Cells
were also stained with an equal concentration of matched fluorescent
labeled isotype control antibodies. All the antibodies were purchased
from BioLegend (San Diego, CA, USA). After the incubation period,
cells were washed three times with FC buffer by centrifugation and
transferred to 5-mL fluorescence-activated cell sorting (FACS) tubes
(12  75 mm) (BD Biosciences, Franklin Lakes, NJ, USA).
Stained cells were acquired on a BD LSRII FACS instrument (BD Bio-
sciences, Franklin Lakes, NJ, USA) and analyzed with FlowJo 7.6.1
(FlowJo LLC, Ashland, OR, USA). From each sample at least
10,000 single-cell events were collected.
Tri-lineage differentiation of ADSCs
By following the international guidelines released by the International
Society for Cellular Therapy (ISCT) and by the International Federa-
tion for Adipose Therapeutics and Science (IFATS),31 the multiline-
age potential differentiation of ADSCs was assessed by adipogenic,
osteogenic, and chondrogenic induction as described in the litera-
ture.25,70 All reagents for differentiation were purchased from
Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated. For adi-
pogenesis, passage 3 ADSCs growing on glass coverslips were incu-
bated for 3 days in adipogenic induction medium (AIM) consisting
of DMEM (Lonza, Basel, Switzerland) supplemented with 10% FBS
(Gibco, Waltham, MA, USA), 1% Pen/Strep, 1 mM dexamethasone,
1 mM insulin, 200 mM indomethacin, and 0.5 mM 3-isobutyl-1-meth-
ylxanthine (IBMX). On the fourth day the AIM was switched to adi-
pogenic maintenance medium consisting of DMEM plus 10% FBS,
1% Pen/Strep, 1 mMdexamethasone, 1 mM insulin, and 200 mM indo-
methacin. The medium was replaced every 3 days with fresh medium.
To assess for spontaneous differentiation, ADSCs were cultured with
complete control medium (DMEM, 10% FBS, and 10% Pen/Strep).
Adipogenic differentiation was assessed after 2 weeks of induction
Figure 8. Effect of ADSCs on survival of murine Hb9-
EGFP-MNs after co-culture with control and ALS-
derived human iAstrocytes
The graph shows the percentage of MNs that survived from
day 1 to day 3 of co-culture with human iAstrocytes in the
presence or absence of mADSCs. The orange bars repre-
sent astrocytes derived from control patients; red bars as-
trocytes carrying the C9orf72 repeat expansion; green bars
astrocytes derived from sporadic ALS patients; and purple
bars astrocytes derived from patients with the SOD1A4V
mutation. MN survival was significantly reduced in iAs-
trocytes derived from ALS patients compared with control
iAstrocytes obtained from healthy control donors. The
presence of ADSCs protected MNs from iAstrocyte ALS
neurotoxicity, restoring MN survival at levels sometimes
comparable to those observed in control non-ALS cultures.
The ability of ADSCs to reduce MN death appeared to be
patient specific, since in the sALS Pat17 and SOD1 Pat100
iAstrocyte cultures ADSCs did not significantly improve MN
survival, although a trend toward improved survival was
observed in both of these cases. Quantification is representative of 3 or 4 independent experiments, where each experiment is in quintuplicate. Data analyzed with 2-way
ANOVA, plus Tukey’s multiple comparison test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ##p < 0.005, ####p < 0.0001. Error bars represent SD. Asterisks denote
significant differences between ADSC-treated and non-treated iAstrocytes; number signs denote significant differences between ALS-iAstrocytes and control iAstrocytes;
phi symbols denote significant differences between ADSC-treated ALS-iAstrocytes and non-treated control iAstrocytes.
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by oil red O (O-R-O) staining.71 Briefly, cells were washed with PBS
and fixed with 4% paraformaldehyde (PFA) pH 7.4 at RT for 20 min.
Next, the wells were washed twice with dH2O for 5 min in agitation
and stained with O-R-O working solution for 15 min at RT. After
incubation, cells were washed three times with dH2O for 5 min in
agitation and rinsed once in 60% isopropanol in order to remove
any excess of stain. Nuclei were counterstained with Mayer’s hema-
toxylin, and coverslips were mounted with aqueous VectaMount
mounting solution (VectaLabs, Burlingame, CA, USA). Images
were then captured with an upright Nikon Eclipse Ni microscope
(Nikon, New York City, NY, USA).
Osteogenesis was induced in confluent ADSC cultures with a differ-
entiation medium consisting of DMEM supplemented with 10%
FBS, 1% Pen/Strep, 0.1 mM dexamethasone, 50 mg/mL ascorbic
acid, and 10 mM b-glycerolphosphate. Every 3 days, cells were fed
with fresh osteogenic differentiation medium for a total of 2 weeks.
For controls, ADSCs were cultured in complete control medium.
Osteogenic differentiation was confirmed by alizarin red staining.72
Cells were gently washed once with PBS and fixed for 30 min at RT
with a fixation solution consisting of 39.7% dH2O, 59.5% acetone,
and 0.8% citrate concentrated solution (sodium citrate tribasic dehy-
drate 1 M). After fixation, cells were washed with PBS and stained
with 2% alizarin red S for 45 min at RT. After the incubation period,
cells were washed at least 5 times with dH2O to remove any trace of
free dye and rinsed in PBS. Coverslips were mounted on glass slides
and visualized with the Nikon Eclipse Ni microscope (Nikon, New
York, NY, USA).
Chondrogenic differentiation was performed on three-dimensional
cell pellets.70 ADSCs were detached with trypsin and centrifuged at
300  g at RT for 4 min. Cells were then counted, and 0.5  106 cells
were aliquoted in 15-mL Falcon tubes. After a further centrifugation
step, the supernatant was removed and pellets re-suspended with
500 mL of chondrogenic differentiation medium consisting of
DMEM containing 1% FBS, 1% Pen/Strep, 1% insulin-transferrin-se-
lenium (ITS) (Gibco, Waltham, MA, USA), 1% sodium pyruvate,
50 mg/mL ascorbic acid, 0.1 mMdexamethasone, and 10 ng/mL trans-
forming growth factor b1 (PeproTech, Rocky Hill, NJ, USA).
Cells were then centrifuged at 300  g for 3 min at RT, and tubes
were placed in an incubator without disturbing the pellet. Freshly pre-
pared chondrogenic medium was changed every day for the first
3 days. From the fourth day onward, medium was changed every
3 days. For non-induced controls, pellets were cultured in the pres-
ence of control medium consisting of DMEM, 1% FBS, and 1%
Pen/Strep.
Chondrogenesis was assessed after 3 weeks of differentiation by
Alcian blue staining.73 Cell pellets were washed twice in PBS and fixed
in PFA 4% at room temperature for 30 min. Pellets were then washed
in PBS and cryo-protected in 30% sucrose (w/v) in PBS at 4C over-
night (O/N). The day after, pellets were embedded in optimal cutting
temperature compound (OCT) (CellPath, Newtown, UK) and rapidly
frozen on dry ice soaked in methanol. Frozen pellets were cut in
20-mm-thickness sections and collected on glass slides. For Alcian
blue staining, tissue sections were acidified for 5 min at RT with
0.1 M HCl. Slides were then stained with Alcian blue 1% in 0.1 M
HCl 1 h at RT. After incubation, sections were rinsed in 0.1 M HCl,
washed with ddH2O, and mounted.
Production and titration of EGFP-expressing lentiviral particles
The pLV-SIN-EGFP vector was a gift from Dr. Evangelia Karyka
(University of Sheffield, Sheffield, UK). The pLV-EGFP plasmid is a
HIV-1-based expression vector in which the transcription of EGFP
is driven by the mouse phosphoglycerate kinase (mPGK) promoter.
The vector contains all the viral processing elements for the produc-
tion of self-inactivating (SIN) third-generation lentiviral particles.
Lentivirus was produced from co-transfection of HEK293T cells with
the transfer plasmid pLV-SIN-EGFP and the three packaging plas-
mids pCMVD8.92, pRSV-Rev, and pMDG2.
One day before transfection, HEK293T cells were plated onto 20 Petri
dishes at a seeding density of 3  106 cells/plate and cultured in
DMEM, 10% FBS, and 1% Pen/Strep. The day after, cells were co-
transfected by the calcium-phosphate method. Each plate was trans-
fected with 13 mg of pLV-SIN-EGFP, 13 mg of pCMVD8.92, 3 mg of
pRSV-Rev, and 3.75 mg of pMDG. After 16 h, fresh medium was
added and cells were cultured for a further 48 h before supernatant
collection. The virus-containing medium was then filtered through
a 0.45-mm filter to remove cells and debris, and a high-titer viral prep-
aration was achieved by ultracentrifugation at 68,580  g for 90 min
at 4C. The virus was resuspended over several hours on ice in 1%
BSA in PBS, aliquoted, and stored at 80C until use.
Vector titration (TU) was performed on HeLa cells with flow cytom-
etry. TU was calculated by quantifying the number of EGFP-positive
HeLa cells after transduction with serial dilutions (102, 103, and
104 mL of vector) of the concentrated lentivirus preparation. Viral
titer was calculated as transduction units per milliliter (TU/mL) using
the volume of virus used for infection.
Lentivirus transduction of ADSCs and long-term cell storage
In order to estimate the optimal titer that would lead to high trans-
duction efficiency and low toxicity, we performed a dose-response
experiment by infecting ADSCs with viral particles at a multiplicity
of infection (MOI) of 10, 40, 80, and 100 in the presence or absence
of 4 mg/mL polybrene (Sigma, St. Louis, MO, USA). Passage 2
ADSCs were seeded at a density of 7,000 cells/cm2 in 12-well plates
and incubated under standard culture conditions for 16 h. Cells were
then transduced for 7 h with a final volume of 0.5 mL/well of virus
before addition of another 0.5 mL/well of fresh complete medium.
After 24 h, lentivirus-containing medium was replaced with fresh
medium and cells were left in the incubator for 72 h. Transduction
efficiency and cell morphology were monitored daily by fluorescent
microscopy before quantification by flow cytometry analysis on
PFA-fixed cells.
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The MOI of 40 in the presence of 4 mg/mL polybrene was used in the
following experiments, as nearly 99% of the cells were positive for
GFP and cell morphology was similar to the non-transduced ADSCs.
After lentivirus infection, passage 2 EGFP-ADSCs were grown to 80%
confluence and collected for long-term cell storage. Briefly, cells were
lifted with trypsin, washed in PBS by centrifugation, and resuspended
in freezing medium consisting of 80% FBS (Gibco, Waltham, MA,
USA), 10% DMEM (Lonza, Basel, Switzerland), and 10% dimethyl
sulfoxide (DMSO) (Sigma, St. Louis, MO, USA) at a concentration
of 1 million cells per milliliter of cryopreservation medium. Cells
were then aliquoted in cryovials, placed in an isopropanol freezing
container, and frozen at80C. After 24 h, cryovials were transferred
in liquid nitrogen.
To revive EGFP-ADSCs, cells were rapidly thawed at 37C, washed in
complete medium by centrifugation, and plated at a concentration of
1  104 cells/cm2. EGFP-ADSCs were then grown for one more pas-
sage before being characterized by flow cytometry and multidifferen-
tiation potential.
Animal experiments
All experiments involving mice were conducted in accordance with
the Animals (Scientific Procedures) Act 1986 under a UK Home
Office project license approved by the Sheffield University Ethical
Review Committee Project Applications and Amendments Sub-
Committee and by the UK Animal Procedures Committee (London,
UK). The mouse colony was maintained in a specific pathogen-free
(SPF) environment before being moved for experiments to a conven-
tional animal facility following the Home Office code of practice for
the housing and care of animals used in scientific procedures (12-h
light/dark cycle and RT maintained at 21C). Each mouse cage floor
was covered with a layer of fine sawdust (Eco-Pure Flakes 6, Date-
sand, UK) and contained a plastic house and paper wool (Datesand,
UK). Female mice from the same litter were housed together in pairs,
triplets, or quadruplets, and rodent diet (Harlan, UK) and water were
provided ad libitum. Transgenic C57BL/6J-Tg (SOD1G93A)1Gur/J
mice of the defined C57BL/6J-OlaHsd inbred genetic background
were used in this study.33 Since there are no significant differences
in disease progression between males and females in our model,33
hemizygous transgenic males were bred with wild-type females to
maintain the SOD1G93A transgene, while hemizygous females were
used for experiments. Transgenic SOD1G93A mice were identified
by PCR amplification of genomic DNA extracted from ear tissue
with QuickExtract DNA Extraction Solution 1.0 (Lucigen, Middleton,
WI, USA). DNA amplification was performed in a 10-mL volume of
5 FIREPol Master Mix Ready to Load (Solis Biodyne, Tartu,
Estonia) and 10 nm of each of the human SOD1 primers (forward
50-CATCAGCCCTAATCCATCTGA-30, reverse 50-CGCGACTAA
CAATCAAAGTGA-30) and mouse IL-2R primers (forward 50-CTA
GGCCACAGAATTGAAAGATCT-30, reverse 50-GTAGGTGGAA
ATTCTAGCATCATC-30). Electrophoresis was performed on a 2%
agarose gel, and bands were visualized at 324 bp for IL-2R and
236 bp for hSOD1 when present.
For the in vivo therapeutic study, we followed the recommendations
for the conduct of pre-clinical studies in the SOD1G93A mouse model
released by the ALS Therapy Development Institute (ALS TDI),
which were successively updated in 2009 following an international
conference held in Germany, 11–13 June 2009.74 To determine group
size, a statistical power analysis using G*Power 3.1. was carried out.75
This ensured reduction in the number of animals used in the exper-
iment to a minimum, in compliance with the guideline on the princi-
ples of regulatory acceptance of 3Rs testing approaches.76 Power
analysis was performed based on the detection of a 10-day shift in
the time taken to reach a 20% decline in rotarod performance. A po-
wer of 80% was used with a two-tailed Student’s t test (a = 0.05, b =
0.8). The analysis indicated that 14 mice per group are required to
detect a 10-day difference in time taken to reach the rotarod decline.
The group size was finally increased by 1 (n = 15) in order to account
for unexpected (unrelated health problems) loss of animals.
Intrathecal transplantation of EGFP-ADSCs via cisterna magna
EGFP-ADSCs were thawed from frozen stocks and cultured for
4–5 days before being used for transplantation. When cultures
reached 80% confluence, cells were detached by trypsinization,
washed in PBS, counted, and resuspended in 200 mL of HypoThermo-
sol FRS solution (BioLife Solutions, Bothell, WA, USA) and stored at
4C until ready to be transplanted. Cells were transplanted into the
CSF of mice through cisterna magna injection. The surgical proced-
ure was adapted from previous studies.77 Before surgery, mice were
placed in an induction chamber and anesthetized with 5% isoflurane
(5 mL/min). Unconscious mice were then shaved and placed prone
on a heat pad, and the head was fixed, with the help of a tooth and
ear bars, to a stereotaxic apparatus. During surgery deep anesthesia
was maintained with isoflurane 1%–2% (2 mL/min). To expose the
atlanto-occipital membrane, the skin was incised from the nuchal
line to the level of the second/third cervical vertebrae and the muscles
separated by blunt dissection. To keep the muscles apart, a pair of mi-
cro-retractors were used. After exposure of the atlanto-occipital
membrane, EGFP-ADSCs were prepared for transplantation. Cells
were spun at 366  g for 4 min and re-suspended in sterile RT PBS
at a concentration of 50,000 cells/mL. For injection, cells were taken
into a Hamilton syringe (702 RN 25 mL) (Hamilton, Reno, NV,
USA). The syringe was then placed in a standard infuse/withdraw
programmable syringe pump (Harvard Apparatus 350, Cambridge,
UK) connected to the micromanipulator on the stereotaxic apparatus.
The needle (Gauge 31, point style 4 at 45) was carefully directed to-
ward the midline of the atlanto-occipital membrane, the dura mater
was pierced, and the needle was withdrawn to allow outflow of
CSF. The needle was then moved forward and stopped 1 mm inside
the cisterna magna. A total of 10 mL of cell suspension corresponding
to 500,000 cells was injected at a rate of 1 mL/min. At the end of the
injection, the needle was kept in place for a further 10 min to avoid
cell leakage and then slowly withdrawn. The dorsal muscles were su-
tured with absorbable 5-0 Vicryl (Ethicon, Somerville, NJ, USA) and
the skin with non-absorbable nylon monofilament (Ethicon, Somer-
ville, NJ, USA). The mouse was then moved in an incubator set at
28C until complete recovery. Mice were able to walk normally
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15 - 25 min post-surgery. For the vehicle group, mice were injected
with 10 mL of sterile PBS.
Behavior tests
Weight was measured twice per week in the afternoon immediately
prior to the rotarod test. The rotarod test was carried out for a
maximum period of 300 s, with the rotarod (Ugo Basile 7650, Gem-
onio, Italy) set to accelerate from 4 to 40 rpm in 270 s. On each testing
day, mice were tested twice, with a rest period of 3 min in between
tests, and latency to fall was recorded in seconds. The highest score
was used for analysis. The first rotarod testing day started at the
age of 30–32 days after the mice received training for 3 consecutive
days. In order to determine rotarod decline, the best score among
the first test and the three training tests was used as peak of perfor-
mance. Rotarod performance was carried out until the end of the
study. Gait parameters were captured with the CatWalk gait system
(Noldus Instruments 7.1, Nottingham, UK) in groups of 5 x
SOD1G93A transgenic mice (ADSC-injected and PBS-injected mice)
at 70 and 84 days of age. Mice were placed on the CatWalk apparatus
in complete darkness and allowed to walk without interference. At
least 6 straight and continuous runs were recorded, and the 3 straight-
est runs were selected for analysis. Gait data were analyzed with the
dedicated CatWalk software (version 7.1). Each paw print was labeled
manually, followed by automatic detection of gait parameters. Neuro-
logical deficit scoring was performed in the afternoon every 3 days
from 60 days of age onward with a system previously described in
the literature.33 Forelimb and hindlimb tremors were individually
scored based on a scale of 0–3 (0 - normal, 1 - mild, 2 - moderate,
3 - strong) during mouse suspension by the tail. At the same time,
hindlimb splay defects were evaluated individually for left and right
limbs on a scale of 0–4 (0 - normal, 1 - mild, 2 - moderate, 3 - strong,
4 - paralyzed). The neurological deficit was delineated by an overall
score (0 - normal, 0.5 - onset, 1 - abnormal gait, 2 - severe waddle,
3 - dragging one hindlimb, 4 - paralysis of one limb) and onset of dis-
ease defined by co-existing hindlimb splay defect and hindlimb
tremor for two consecutive tests. All behavioral tests were performed
by the same investigator, who was blinded to the treatment group.
Tissue collection and processing for engraftment qualitative
studies
Mice were sacrificed with an anesthetic overdose by intraperitoneal
injection of pentobarbitone (2.5 mL/kg) and perfused with 7.5 mL of
cold PBS, followed by 20 mL of 2% PFA in PBS. The whole skull and
vertebral column were post-fixed in 2% PFA at 4C O/N. The
following day, dissection of whole CNS with intact dura mater was
performed under the microscope. The dissection protocol was
adapted from the literature.32 After extraction of the brain from
the skull and spinal cord from the column, tissue was cryoprotected
by immersion in 20% sucrose (Sigma, St. Louis, MO, USA) in PBS at
4C O/N. The spinal cord was then sectioned into cervical, thoracic,
and lumbar segments and the brain dissected into forebrain,
midbrain, and hindbrain. Tissue was finally frozen in OCT medium
(CellPath Ltd, Newtown, UK) over methanol/dry ice and stored at
80C.
Samples were sectioned at 20-mm thickness with the use of a cryostat
and mounted on uncoated glass slides. Slides were dried at 37C for
30 min, washed in PBS with gentle agitation (3  10 min) at RT,
and finally mounted in Vectashield aqueous hard-set mounting
containing 40,6-diamidino-2-phenylindole (DAPI) (VectaLabs,
Burlingame, CA, USA). Slides were left to air-dry in the dark at RT
O/N. Images were captured with an IN Cell 2000 analyzer (GE
Healthcare, Chicago, IL, USA).
Immunohistochemistry
Under terminal anesthesia, mice were perfused with 8 mL of ice-cold
PBS followed by perfusion with 10 mL of ice-cold 4% PFA. The spinal
column was collected and post-fixed O/N in 4% PFA/PBS at 4C. The
following day, the spinal cord was dissected from the column, washed
in PBS, and divided into cervical, thoracic, and lumbar segments. The
lumbar enlargement (12mm) was cut in half and embedded in paraffin
within a single block with the twomedian extremities oriented upward.
Tissue was then sliced at 10-mm thickness with a microtome. Sections
were mounted serially over series of 5 slides, with 5 sections being dis-
carded in between series, for a total of 60 slides covering 4.8 mm of spi-
nal cord tissue. This ensured that there was a distance of at least
100 mm between serial sections. Each slide contained 8 sections. Sec-
tions were rehydrated by immersion in alcohol gradients using the
following sequence: 2  5 min in xylene, 5 min in 100% ethanol,
5 min in 95% ethanol, 5 min in 70% ethanol, and 5 min in water. After
deparaffinization, heat-induced epitope retrieval was performed. Slides
were completely submerged in Access Super RTU pH 8 (Menarini,
Florence, Italy) and placed in an antigen access unit (Menarini, Flor-
ence, Italy) for 30 min at 125C with a pressure of 20 psi. At the end
of the cycle, slides were left to cool at RT and washed in PBS for
10 min with gentle agitation. Sections were then blocked/permeabi-
lized for 20 min at RT with 5% BSA, 0.25% Triton X-100 (Sigma, St.
Louis, MO, USA) in PBS. After blocking/permeabilization, slides
were co-immunostained for mouse GFAP (chicken polyclonal,
1:500) (Abcam, Cambridge, UK) and for mouse Iba1 (rabbit poly-
clonal, 1:500) (GeneTex, Irvine, CA, USA) diluted in 1% BSA, 0.25%
Triton X-100/PBS at 4C O/N. Slides were then given 6 quick washes
and 3  8 min washes in PBS, blocked in 5% BSA/PBS for 10 min at
RT, and incubated with the secondary antibodies conjugated to Alexa
Fluor 488 (1:1,000) (Thermo Fisher, Waltham, MA, USA) or Alexa
Fluor 555 (1:1,000) Thermo Fisher, Waltham, MA, USA) at RT for
90 min. After incubation, slides were washed with 2 quick washes in
PBS, 4  8 min washes in PBS, and 1  5 min wash in distilled water
in the dark. Slides were dried to remove water excess, mounted with
Vectashield hard set aqueous solution with DAPI (VectaLabs, Burlin-
game, CA, USA), and left to dry at RT O/N in the dark. Images were
captured with the IN Cell 2000 analyzer (GE Healthcare, Chicago,
IL, USA) and analyzed with the GE Developer Toolbox 1.9 (GE
Healthcare, Chicago, IL, USA). GFAP and Iba1 staining was captured
within each ventral horn of each spinal cord section (8 sections/mouse)
at a magnification of 60. GFAP staining was segmented by intensity
level with a threshold greater than 220 gray levels, followed by a sieve
filter over 4 mm. Total staining area (mm2) and main staining index
[(unstained pixels – stained pixels)/2  SD] were recorded. Iba1
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staining was segmented by intensity level with a threshold greater than
200 gray levels, followed by a sieve filter over 4 mm. Total staining area
(mm2) was recorded.
Nissl staining and motor neuron counts
Paraffin serial sections of lumbar spinal cord were processed for Nissl
staining. The staining was performed on every 5th section (total of 12
slides per mouse with 8 sections per slide) covering a total length of
4.8 mm of the lumbar spinal cord, with at least 100 mm of space be-
tween each section. Nissl staining was performed according to the
literature. Briefly, sections were dewaxed in xylene, rehydrated
through graded alcohols, and stained with pre-filtered 0.1% cresyl
fast violet for 20 min. Sections were then rinsed quickly in distilled
water and differentiated in 0.25% ethanoic acid for 10 s. After washing
in distilled water, sections were dehydrated by immersion baths in
crescent graded alcohols with the following sequence: 5 min in 70%
ethanol, 5 min in 95% ethanol, 2  5 min in 100% ethanol, and
5 min in xylene to clear. Slides were dried, mounted in permanent
mounting medium (H-5000, VectaMount), and dried at 37C O/N.
Nissl-positive a-MNs were identified and counted depending on their
topography, morphology, and size. a-MNs were defined as multipolar
cells located in the ventral horn of the lumbar spinal cord, character-
ized by the presence of a large nucleus with intensely labeled nucleoli
and a diameter size of at least 25 mm. A total of 96 sections (192
ventral horns) were screened for each mouse (n = 6 per group).
MN counting was performed by the same investigator, who was
blinded to the treatment group.
Isolation and culture of mouse cortical astrocytes
Mouse cortical astrocytes were isolated from symptomatic (90 days)
female transgenic SOD1G93A and control sex- and age-matched
NTg mice. Isolation and culture of astrocytes was performed as pre-
viously described with minor modifications.78Mice were sacrificed by
cervical dislocation, and brains from 3 mice were isolated and pooled
together. Cerebellum and meninges were carefully dissected, and tis-
sue was digested with papain (200 U/mL) (Sigma, St. Louis, MO,
USA) diluted in enzymatic buffer (116 mM NaCl, 5.4 mM KCl,
26 mM NaHCO3, 1 mM NaH2PO4, 1.5 mM CaCl2, 1 mM MgSO4,
25 mM glucose, 1 mM cysteine in ddH2O). After DNase treatment
and mechanical dissociation, tissue homogenate was filtered through
a 70-mm cell strainer and cell isolated by density gradient using 20%
Percoll solution (Sigma, St. Louis, MO, USA). The cell pellet was re-
suspended in complete astrocyte medium (DMEM) (Fisher Scientific,
Hampton, NH, USA), 10% FBS (Life Science Production, Bedford,
UK), and 1% Pen/Strep (Gibco, Waltham, MA, USA) and plated in
a standard culture flask previously pre-coated with 0.01% poly-L-
ornithine (Sigma, St. Louis, MO, USA). Cells were grown in an incu-
bator at 37C with 20% O2, 5% CO2 and 95% humidity. Medium was
replaced every 3 days for 14 days. When cultures reached conflu-
ence, flasks were placed on an orbital shaker at 230 rpm, 37C for
12 h to remove contaminating microglia. mAstrocytes were then de-
tached with mild trypsinization and expanded.79 For these experi-
ments, mAstrocytes were used at passage 4.
Reprogramming of human fibroblasts into neural progenitor
cells (iNPCs)
Skin biopsy collection from ALS patients and healthy donors (Table
S1) was approved by the Research Ethics Committee of Sheffield
(study number STH16573, reference 12/YH/0330) or by the Institu-
tional Review Board of the Ohio State University (ethics number
IRB08-00402) after informed consent was obtained.
Fibroblasts from 2 non-ALS control subjects and 2 C9orf72, 2
SOD1A4V, and 2 sporadic ALS patients were reprogrammed into neu-
ral progenitor cells (induced NPCs [iNPCs]) as previously
described.30 Fibroblasts were grown into one well of a six-well plate
for 24 h before being transduced with retroviral vectors expressing
Oct4, Sox 2, Klf 4, and c-Myc. Cells were allowed to recover for
1 day in basal fibroblast medium composed of DMEM (Gibco,
Waltham,MA, USA) and 10% FBS (Life Science Production, Bedford,
UK) and switched to NPC conversion medium consisting of DMEM/
F12 (1:1) GlutaMax (Gibco, Waltham, MA, USA), 1% N2 (Gibco,
Waltham, MA, USA), 1% B27 (Gibco, Waltham, MA, USA),
20 ng/mL FGF2 (PeproTech, Rocky Hill, NJ, USA), 20 ng/mL EGF
(PeproTech, Rocky Hill, NJ, USA), and 5 ng/mL heparin (Sigma,
St. Louis, MO, USA). After morphology changes, rosette-like struc-
tures were switched to NPC proliferation medium consisting of
DMEM/F12 (1:1) GlutaMax, 1% N2, 1% B27, and 40 ng/mL FGF2,
where iNPCs were expanded.
Differentiation of iNPCs into iAstrocytes
iAstrocytes were obtained as previously described.30 iNPCs were
seeded in 10-cm dishes coated with fibronectin and induced to differ-
entiate for 7 days by culture in astrocyte proliferation medium
composed of DMEM (Fisher Scientific, Hampton, NH, USA) con-
taining 10% FBS (Life Science Production, Bedford, UK) and 0.2%
N2 (Gibco, Waltham, MA, USA).
Hb9-EGFP motor neurons
Murine Hb9-EGFP MNs were obtained from mESCs containing an
EGFP gene under the MN-specific promoter Hb9 (kind gift from
Thomas Jessell, Columbia University, New York, NY, USA). Hb9-
EGFP mESCs were differentiated as previously described.80 At the
end of the differentiation (7 days), the Hb9-EGFP MN enriched frac-
tion was obtained by embroid body dissociation with 20 U/mL papain
(Sigma, St. Louis, MO, USA) as previously described.81
Hb9-EGFP-MN, mouse astrocyte, and ADSC separated co-
cultures
For co-culture experiments, three separated astrocyte preparations
per genotype (SOD1G93A and NTg) were established (biological rep-
licates). Passage 4 mAstrocytes from symptomatic (90 day old)
SOD1G93A or NTg age-matched control mice were seeded in triplicate
(technical replicate) onto 1 well of a 24-well plate previously coated
with 1:1,000 poly-L-ornithine (Sigma, St. Louis, MO, USA) and
laminin 1:200 (Sigma, St. Louis, MO, USA), at a concentration of
50,000 cells/well. mAstrocytes were maintained for 24 h in astrocyte
basal medium (DMEM, 10% FBS, 1% Pen/Strep). On the same day,
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30,000 passage 5 ADSCs were plated onto sterile glass coverslips
(22 mm2) containing 2-mm2 paraffin wax dots. The next day, the
Hb9-EGFP MN enriched fraction was obtained and 30,000 cells/
well were plated onto the mAstrocyte monolayer in 1 mL of MN me-
dium consisting of KnockOut DMEM, F12 medium, 10% KnockOut
Serum Replacement, 1 mM L-glutamine, 0.5% (w/v) glucose, 1% N2,
0.0016% (v/v) 2-mercaptoethanol, 20 ng/mL brain-derived neurotro-
phic factor (BDNF) (PeproTech, Rocky Hill, NJ, USA), 40 ng/mL
ciliary neurotrophic factor (CNTF) (PeproTech, Rocky Hill, NJ,
USA), and 20 ng/mL glial cell-derived neurotrophic factor (GDNF)
(PeproTech, Rocky Hill, NJ, USA). Before addition of the MN, the
astrocyte medium was removed and astrocytes washed with PBS. Af-
ter 5 h, each coverslip containing the ADSCs was washed in PBS and
laid onto the astrocyte/Hb9-EGFP MN mixed co-culture. Thus,
ADSCs were only physically separated from astrocytes and MNs.
Every alternate day, 500 mL of medium was replaced with fresh com-
plete MN medium until day 7 of co-culture. Hb9-EGFP MNs were
imaged with the IN Cell 2000 analyzer (GE Healthcare, Chicago,
IL, USA) 24 h after the initiation of the co-culture to measure the
number of cells at day 1. Plates were then imaged at day 7. The num-
ber of viable MNs was counted with the Columbus Data Storage and
Analysis System (RRID:SCR_007149; Perkin Elmer, Waltham, MA,
USA). Only GFP-positive motor neuronal cell bodies with at least 2
cell processes were counted as viable cells. Finally, the percentage of
MN survival was calculated as the number of viable MNs at day 7
as a percentage of the number of viable MNs at day 1.
Hb9-EGFP MN, human iAstrocyte, and ADSC separated co-
cultures
Human iAstrocytes were grown in 10-cm dishes in complete
iAstrocyte proliferation medium (DMEM, 10% FBS, 0.2% N2). At
day 6 of differentiation, cells were lifted with Accutase and plated
in quintuplicate into one well of a 24-well plate coated with 1:400
fibronectin. Cells were seeded at a concentration between 10,000
and 40,000 cells/well depending on the cell line. ADSCs were plated
onto glass coverslips (22 mm2) containing paraffin wax dots at a
concentration of 30,000 cells/well. After 24 h (day 7 for iAstrocyte
differentiation), 40,000 Hb9-EGFP MNs were seeded on top of the
iAstrocytes and medium was switched to MN medium (KnockOut
DMEM, F12 medium, 10% KnockOut Serum Replacement, 1 mM
L-glutamine, 0.5% (w/v) glucose, 1% N2, 0.0016% (v/v) 2-mercaptoe-
thanol, 20 ng/mL BDNF, 40 ng/mL CNTF, and 20 ng/mL GDNF).
After 5 h, the coverslips containing ADSCs were flipped over the
iAstrocytes/MN mixed co-culture to obtain the triple-separated
co-culture. The following day, plates were imaged with the IN Cell
2000 analyzer (GE Healthcare, Chicago, IL, USA) for quantification
of viable MNs at day 1. Hb9-EGFP MNs were imaged again at day
3 and the percentage of MN survival calculated as viable cells at
day 3 as a percentage of viable MNs at day 1.
Mouse astrocyte and ADSC separated co-cultures
mAstrocytes derived from SOD1G93A and age-matched NTg mice
obtained from three separate preparations were plated onto
24-well plates coated with 1:1,000 poly-L-ornithine (A-004-C,
Sigma-Aldrich) at a concentration of 50,000 cells per well. mAstro-
cytes were allowed to recover for 2 days before addition of 30,000
ADSCs/well previously seeded onto glass coverslips containing
wax dots. Separated co-cultures were maintained for 48 h in com-
plete mAstrocyte medium (DMEM, 10% FBS, 1% Pen/Strep). Empty
coverslips were used as a negative control. At the end of the co-cul-
ture period, for supernatant protein analysis, the coverslips contain-
ing ADSCs were removed, washed in PBS, and cultured for a further
24 h in 500 mL of control serum-free medium. mAstrocyte cultures
were also washed in PBS twice, and 300 mL of fresh serum-free me-
dium was added. After 24 h, the supernatant from both astrocytes
and ADSCs was collected, spun at 600  g at 4C for 10 min, and
snap frozen in liquid nitrogen. Samples were stored at 80C until
ready to use. After supernatant collection, mAstrocytes were fixed
with 4% PFA (v/v) in PBS for 10 min and stained with Hoechst
33342 Solution (62249, Thermo Fisher Scientific) diluted 1:5,000.
Plates were then imaged with the IN Cell 2000 analyzer (GE Health-
care) and cell nuclei counted with the Columbus Data Storage and
Analysis System (RRID:SCR_007149; Perkin Elmer, Waltham,
MA, USA).
Multiplex bead-based immunoassay
Soluble cytokines in supernatants were measured with the use of the
BD Cytometric Bead Array (CBA) Flex Set multiplexed bead-based
immunoassay (BD Biosciences), which allows up to 30 analytes to
be measured simultaneously. Samples were analyzed for IL-6, IL-
1b, TNF-a, and MCP-1. The assay was performed according to the
manufacturer’s instructions, and samples were acquired on an Attune
dual-laser flow cytometer (Thermo Fisher, Waltham, MA, USA). The
data files were collected as Excel sheets and analyzed with GraphPad
7. First, a nonlinear regression standard curve (Curve Fit) was gener-
ated. This was then used to extrapolate the sample values. Protein
concentration (pg/mL or pg/mL) for each well/sample was finally
normalized to the number of cells counted at the end of the experi-
ment in that specific well.
ELISA
VEGF-A and IGF-1 protein concentrations in the supernatant
collected from mAstrocytes and ADSCs after separated co-culture
were quantified by sandwich enzyme-linked immunosorbent assay
(ELISA) using commercial ELISA kits.
For VEGF-A measurement, the mouse VEGF-A Platinum ELISA kit
(BMS619/2, Thermo Fisher Scientific) was used according to the
manufacturer’s instruction. IGF-I protein concentration was quanti-
fied with the mouse IGF-1 ELISA Kit (EMIGF1, Thermo Fisher Sci-
entific) according to the manufacturer’s instructions. Before starting
the protocol, samples stored at 80 were thawed on ice and diluted
with the assay diluent provided in the kit. The standard and each
sample were loaded in duplicate into the specific antibody-pre-coated
96-well strip plate provided in the kit and the manual instructions fol-
lowed. At the end of the protocol, absorbance was read at 450 nmwith
the PHERAStar microplate reader (BMG, Labtech) and absorbance
values transferred to an Excel data sheet. Data were finally analyzed
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with GraphPad 7. Briefly, the optical density value from the control
(medium alone) was subtracted from the standard and sample read-
ings. Data were then plotted on GraphPad 7, and a nonlinear
sigmoidal standard curve (Curve Fit) was fitted. Protein concentra-
tion in the samples was then extrapolated and normalized to the num-
ber of cells counted at the end of the co-culture.
Statistical analysis
All statistical analyses were performed with GraphPad Prism 7
(GraphPad, San Diego, CA, USA). The 1-way ANOVA with Tukey’s
multiple comparison test, 2-way ANOVA with Sidak’s multiple com-
parison test, 2-way ANOVAwith Bonferroni post hoc test, Student’s t
test, or Mann-Whitney U test was used depending on the number of
variables in each experiment. Statistical significance was considered
with a p <0.05.
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